Novo Nordisk
NVO
Novo Nordisk (NVO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.78
- EPS estimate
- $0.80
- EPS surprise
- −2.73%
- Revenue surprise
- −0.02%
- Revenue
- $11.0B
- Revenue estimate
- $11.0B
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.80 | $0.78 | −2.73% | $11.0B | SEC |
| Q1 2026 | May 6, 2026 | $0.91 | $1.04 | +14.35% | $11.0B | SEC |
| Q4 2025 | Feb 3, 2026 | $0.93 | $0.95 | +3.06% | $12.5B | SEC |
| Q3 2025 | Nov 5, 2025 | $0.76 | $0.69 | −9.41% | $11.5B | SEC |
| Q2 2025 | Aug 6, 2025 | $0.92 | $0.93 | +1.02% | $12.0B | SEC |
| Q1 2025 | May 7, 2025 | $0.91 | $0.99 | +8.78% | $11.9B | SEC |
| Q4 2024 | Feb 5, 2025 | $0.83 | $0.89 | +6.56% | $12.0B | SEC |
| Q3 2024 | Nov 6, 2024 | $0.88 | $0.88 | +0.19% | $10.3B | SEC |
| Q2 2024 | Aug 7, 2024 | $0.71 | $0.66 | −7.04% | $10.0B | SEC |
| Q1 2024 | May 2, 2024 | $0.75 | $0.81 | +8.33% | $9.4B | SEC |
| Q4 2023 | Jan 31, 2024 | $0.67 | $0.72 | +6.77% | $9.6B | SEC |
| Q3 2023 | Nov 2, 2023 | $0.68 | $0.71 | +4.57% | $8.4B | SEC |
| Q2 2023 | Aug 10, 2023 | $0.68 | $0.64 | −5.87% | $8.0B | SEC |
| Q1 2023 | May 4, 2023 | $0.62 | $0.65 | +4.31% | $7.9B | SEC |
| Q4 2022 | Feb 1, 2023 | $0.42 | $0.43 | +2.57% | $6.9B | SEC |
| Q3 2022 | Nov 2, 2022 | $0.41 | $0.42 | +3.27% | $6.0B | — |
| Q2 2022 | Aug 3, 2022 | $0.41 | $0.40 | −2.71% | $5.6B | — |
| Q1 2022 | Apr 29, 2022 | $0.42 | $0.44 | +4.21% | $6.0B | — |
| Q4 2021 | Feb 2, 2022 | $0.36 | $0.36 | +1.35% | $5.8B | — |
| Q3 2021 | Invalid Date | $0.39 | $0.41 | +5.66% | $5.5B | — |
Quarterly revenue
Frequently asked questions
When did Novo Nordisk (NVO) last report earnings?
Novo Nordisk last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did NVO beat earnings estimates?
No. Novo Nordisk reported EPS of $0.78 for Q2 2026 against a $0.80 estimate — a 2.73% miss.
How much revenue did NVO report last quarter?
Novo Nordisk reported $11.0B in revenue for Q2 2026, against a consensus estimate of $11.0B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.